Atlas Trials

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

Clinical trial NCT00001056 · COMPLETED

Trial details

NCT number
NCT00001056
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
HIV Infections
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.